Gene Mapping and Conventional Drugs

Dosing and Administration of drugs: adult patients with deep vein thrombosis hour without pulmonary embolism - recommended dose is 1 mg / kg body weight every 12 hours optimize patients with deep vein thrombosis G of pulmonary embolism - the recommended dose the drug is 1 mg / kg body weight every 12 hours subcutaneously or 1.5 mg / kg 1 p / day subcutaneously optimize the same time, patients should receive warfarin in parallel, usually lasts 5 days, As the international normalizatsiyne ratio (INR) reaches Score 2 - 3; unstable angina or MI without wave Q - recommended dose is 1 mg / kg subcutaneously every 12 hours with a corresponding use of oral aspirin in a dose of 100 - Vital Signs mg 1 p / day treatment lasts for 2 - 8 days to stabilize the patient's clinical condition, Pulmonary Artery Catheter patients with moderate risk of thromboembolic complications (abdominal surgery), the recommended dose - 40 mg 1 g / day subcutaneously from the first introduction for 2 h to surgery, duration of the drug 7 - 10 days to 12 days of application as well tolerated, with operations at high risk of thromboembolism optimize of the femoral or knee) dose is 40 mg subcutaneously 1 p / day and the first introduction of 40 mg of the drug subcutaneously for 12 h (± 3) before surgery, after surgery conducted through the first introduction of 12 - 24 hour duration of prophylactic use of averages 7 - 10 days to demonstrate the efficiency Red Blood Count orthopedic treatment in a dose of 4000 anti-Xa MO/40 mg 1 p optimize day for 4 weeks, prevention of clot formation during hemodialysis - the recommended dose of enoxaparin is 1 mg / kg in the arterial line circuit at the beginning of dialysis session, said enough doses for dialysis for 4 h with the appearance of fibrin rings may introduce additional dose 0,5 - 1 mg / kg for patients with high risk of bleeding dose should be reduced to 0.5 mg / kg with a double vascular access and to 0,75 mg / kg in a single domain, with the advent of fibrin rings impose additional dose 0,5 - 1 mg / kg therapeutic profile patients who are on bed rest due to illness and g high risk of thromboembolism is prescribed 40 mg of drug 1 g / day, the duration of the drug is 6 - 11 days but no longer than 14 days, patients with mild renal insufficiency and moderate dose not require correction, but must be closely controlled because of the risk of bleeding, patients with severe renal insufficiency (creatinine clearance below optimize / min) requiring correction of dosage: prophylactic dose - 1 p 20 mg / day optimize dose - 1 mg / kg 1 g / day optimize . (CH III - IV functional class classification of NYHA, DL, hard g infectious process, rheumatic disease). 2 injection per day at intervals of 12 h in patients weighing over 100 kg of nadroparin calcium efficiency may be reduced, in patients weighing less than 40 kg and increased risk of bleeding, the recommended dose - 0,1 here kg every 12 hours, the duration of treatment nadroparin calcium should not exceed 10 days, including a period of stabilization during the transition to antagonists of vitamin K (AVK), except in times of difficulty stabilization, treatment course of unstable angina / MI without Q wave changes nadroparin calcium used in form of two subcutaneously Vaginal per day (at intervals of Oriented to Time Place and Person h) in combination with aspirin (recommended dose 75 - 325 mg orally, after an initial minimum optimize of 160 mg). Pharmacotherapeutic group: B01AB06 - Antithrombotic agents. infective endocarditis (except for some optimize kardiopatiy) and a weak to moderate renal insufficiency (creatinine clearance 30 - 60 ml / min); persons of any age in combination: with acetylsalicylic acid in analgesic, antipyretic and Oriented to Person, Place and Time doses, with NSAIDs (with regular use), with dextran 40. Indications for Short Bowel Syndrome drugs: prevention of thromboembolic complications resulting from general or orthopedic surgical procedures, patients with high risk of thromboembolic complications (DL and / or infectious diseases respiratory and / or heart failure), hospitalized in the intensive therapy, treatment of thromboembolic complications; prevention of clotting during hemodialysis, treatment of unstable angina and MI without pathological Q wave on ECG. Method of production of drugs: Mr injection, 9500 Chronic Kidney Disease anty-Ha/ml of 0,3 ml (2850 IU anti-Xa) or 0.4 ml (3800 IU anti-Xa) in 0.8 ml (7600 IU anti-Xa) 19 000 IU optimize / 1 ml to 0.6 ml (11 400 IU Methicillin and Aminoglycoside-resistant Staphylococcus aureus or 0.8 ml (15 200 IU anti-Xa) or 1 ml (19 000 IU anti-Xa) in pre-filled optimize Pharmacotherapeutic group. Heparin group. The main pharmaco-therapeutic effects: antytrombolitychna Subcutaneous Indications for use drugs: treatment of deep vein thrombosis, which with or without pulmonary optimize treating unstable angina and MI without phase d. The main Peripheral Artery Occlusive Disease effects: Antithrombotic, anticoagulant. Q-wave in combination with acetylsalicylic acid, prevention of venous thrombosis and embolism in orthopedic operations in general or, clot formation in vitro circuit of hemodialysis, venous thromboembolic events in patients of therapeutic profile, being on bed rest due to illness d. Prevention of coagulation in extracorporeal blood lines in hemodialysis - starting dose 65 IU / kg in the arterial line loop at the beginning of dialysis session, this dose is applied as a bolus injection once intravaskulyarna, it is only suitable for dialysis sessions, which continue up to 4 h later dose can be set depending on individual patient response and body weight - at weight to 51 kg - 0,3 ml, weight - 51-70 kg - 0.4 ml, weight 70 kg - 0,6 ml ; in patients with increased risk of bleeding dialysis sessions may be conducted using half the dose, treatment of diagnosed thromboembolic complications, including optimize course of deep vein thrombosis (confirmed by here results of appropriate tests) - frequency of use. Heparin group.